Boston Scientific shares have been under heavy pressure in recent months, with the stock down more than 50% year to date as investors digested a steady stream of growth downgrades from company guidance.
Despite the market’s pessimism, the analyst community remains relatively constructive—though investors are likely focused on whether Boston Scientific can stabilize demand trends, particularly in its Watchman franchise, before expectations reset further.
Key takeaways
- Price move: Boston Scientific shares have fallen by more than 50% year to date.
- Catalyst: Management repeatedly walked back growth outlook, including updated comments tied to lower Watchman stand-alone procedure usage.
- What investors are watching: Whether the company can halt the downward revisions and deliver stronger-than-guided organic growth in upcoming quarters.
- Street stance: Even with a difficult tape, 27 of 31 analysts still rate the stock as equivalent to a buy.
- Implication: The gap between the stock’s valuation and higher price targets may narrow only if growth accelerates faster than investors currently expect.
What drove Boston Scientific’s slide
Boston Scientific has been lowering expectations for its growth trajectory throughout the year. In February, management guided organic sales growth of 10% to 11%. Investors initially reacted negatively to a later update in which 2025 growth was described at 19.5%, setting up a discrepancy between earlier expectations and the company’s subsequent outlook.
Guidance adjustments continued. In April, Boston Scientific lowered its full-year 2026 organic revenue outlook to a range of 6.5% to 8%. Then, in late May, the company walked things back again, citing what it described as declining usage of Watchman stand-alone procedures—procedures that use Boston Scientific’s Watchman heart implant without broader combined interventions.
Watchman stand-alone demand and the timing of growth
During the late-May update, CEO Michael Mahoney said the company would likely report “flat dollar growth from first quarter to second quarter,” and “likely in the third quarter.” The guidance change underscored that the weakness tied to Watchman stand-alone procedures is not confined to a single quarter and could weigh on near-term results.
From an investor perspective, this matters because quarterly inflections often drive revisions. When management frames multiple consecutive periods as flat, analysts and investors typically become less willing to underwrite a rapid return to higher growth without clear evidence that procedure volumes are stabilizing.
Why lofty price targets could face pressure
While the stock’s performance has been sharply negative, Wall Street’s rating mix remains supportive. According to the article, 27 of 31 analysts covering Boston Scientific assign ratings that are equivalent to a buy. The consensus price target highlighted in the piece is $78 per share, implying potential upside of 65% from the then-current level cited by the article.
However, the same coverage notes that rebuilding a “premium” valuation would likely require a growth recovery that is faster than what the market is currently pricing. Boston Scientific trades at a forward valuation in the mid-teens, positioned in line with other medical device peers such as Abbott Laboratories and Medtronic.
In practical terms, if Boston Scientific’s growth does not re-accelerate, investors may keep it grouped with the peer set rather than rerating it above the industry. Moreover, if results in the second quarter and associated guidance fail to improve, the higher price targets referenced by analysts could trend downward—especially if management continues to adjust expectations.
Bigger picture: how revisions shape medical device sentiment
Boston Scientific’s experience reflects a broader challenge for medical device companies when procedure dynamics shift faster than investors anticipate. Watchman-related demand appears to be a focal point for both near-term revenue visibility and longer-term confidence in the durability of procedure volume trends.
As revisions accumulate, the market often demands clearer proof points—such as improving procedure usage, stronger guidance commentary, or evidence that category weakness is stabilizing—before it restores optimism. Even when analysts remain positive in aggregate, valuation and expectations can diverge sharply from the current business momentum.
What to watch next
Investors are likely to key in on Boston Scientific’s upcoming quarterly results and any further guidance updates, particularly around Watchman stand-alone procedures. With management indicating flat dollar growth across consecutive quarters, the next read-through on demand and guidance will be central to whether the stock’s slide slows and whether analyst price targets come under renewed pressure—or hold steady.
